Wednesday, March 19, 2014 1:27:06 PM
Editor's Corner
The FDA vs. the flash mob: Hard questions as parents demand unproven drugs
By John Carroll
Last week the parents of 7-year-old Josh Hardy managed to whip up a media tempest big enough to get the biotech Chimerix ($CMRX) and the FDA to work out a pilot study so that their child could be treated after their compassionate use request was denied, alongside many others. Now the parents of another young boy afflicted by a terrible disease are using some interesting PR tactics in an attempt to achieve a much larger goal: Push the FDA to approve experimental drugs for Duchenne muscular dystrophy (DMD) ahead of pivotal studies in the hope that it could let their young son, Ryan Dunne, live a "healthy life."
The local CBS affiliate in Colorado turned out for a flash mob demonstration yesterday, with protesters chanting Ryan's name and giving his parents a chance to highlight their campaign to get 100,000 signatures together to push the FDA to make unapproved DMD drugs available to a young patient population with no therapies approved for the ultimately lethal muscle-wasting disease. Other parents have been turning out in large groups to give FDA officials an earful on the same point. And the "Race to Yes" campaign today added heat with their own statement backing the petition, which is specifically designed to get an accelerated approval for Sarepta's ($SRPT) eteplirsen.
"We don't have time to wait for the FDA," says Jennifer Dunne in her appeal at helpryandunne.com. "We need to do it now," says Ryan's father, adding that his son can't wait years for the FDA to act.
"Every day that the FDA stalls, Duchenne takes children's lives," said Tracy Seckler, the parent of a child with DMD, in a statement. "The FDA claims this is a priority, but they've been sending us the same bureaucratic form letter for several months. If they grant accelerated approval, our children could be the first generation of Duchenne patients to survive."
The campaign raises compelling questions. Does the FDA have a responsibility to allow children access to unproven drugs, provided there's evidence of their safety and the possibility of a positive outcome--of any kind? A group of companies, in particular Sarepta, Prosensa ($RNA) and PTC Therapeutics ($PTCT), have all provided some signals from the data that could indicate a benefit. But Sarepta only has data from a tiny study the agency has already questioned, looking to a pivotal study to decide whether the drug really works. Prosensa's drug failed a Phase III study conducted by GlaxoSmithKline ($GSK). PTC's earlier study for DMD also failed. And all three biotechs insist that there are compelling signs that the drugs may work for some of these boys.
If the FDA eventually decides to capitulate on this point, the biotechs would have a chance to market drugs to children. That could set up another showdown with restive private payers which may well reject covering drugs that are green-lighted without solid evidence of efficacy, approved under traditional guidelines. And that might leave parents to pay a high cost for unproven medications which may have no more effect on the disease than a placebo.
Parents and children don't want to hear about traditional guidelines when they reflect on what's happening to their child. The public will side with the victims, and that leaves the FDA caught between the high R&D standards it's mandated to uphold and the passions aroused by parents, the victims of disease and protesters.
There are no easy answers here. Just hard questions. -- John Carroll, editor-in-chief
All I say is IMHO and not to be construed as investment advice. I know nothing, as informed frequently by my wife.
Recent RNA News
- Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 04/22/2024 08:05:00 PM
- Avidity Biosciences to Participate in Upcoming Investor Conferences • PR Newswire (US) • 03/27/2024 01:00:00 PM
- Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 03/21/2024 08:05:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:23:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:53:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 12:07:00 PM
- Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial • PR Newswire (US) • 03/04/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 09:31:50 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/29/2024 09:19:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:06:10 PM
- Avidity Biosciences Honors Rare Disease Day® • PR Newswire (US) • 02/29/2024 05:00:00 PM
- Avidity Biosciences Announces Oversubscribed $400 Million Private Placement • PR Newswire (US) • 02/29/2024 12:00:00 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 02/28/2024 10:32:43 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/28/2024 09:17:47 PM
- Avidity Biosciences Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Highlights • PR Newswire (US) • 02/28/2024 09:05:00 PM
- Avidity Biosciences to Participate in Upcoming Investor Conferences • PR Newswire (US) • 02/27/2024 02:00:00 PM
- Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 02/21/2024 09:05:00 PM
- Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping • PR Newswire (US) • 02/20/2024 02:00:00 PM
- Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference • PR Newswire (US) • 02/15/2024 10:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/02/2024 05:08:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 08:13:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 08:12:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/23/2024 08:11:51 PM
- Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 01/22/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 01:36:20 PM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM